Alex Sparreboom, PhD

Alex Sparreboom, PhD

Associate Member, St. Jude Faculty

Departments

Pharmaceutical Sciences

Contact Information

Alex Sparreboom, PhD
Pharmaceutical Sciences
MS 313, Room I5308
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105-3678
Email: alex.sparreboom@stjude.org
Phone: (901) 595-5346
FAX: (901) 595-3125

Education

BS - Utrecht University, Utrecht, the Netherlands (1989)
MS - Utrecht University, Utrecht, the Netherlands (1993)
PhD - Utrecht University, Utrecht, the Netherlands (1996)


Research Interests


Selected Publications

Hu S, Mathijssen RH, De Bruijn P, Baker SD, Sparreboom A. Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations. Br J Cancer 110: 894-898, 2014. PMCID:PMC3929889

Sprowl JA, Van Doorn L, Hu S, Van Gerven L, De Bruijn P, Li L, Gibson AA, Mathijssen RH, Sparreboom A. Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance. Clin Pharmacol Ther 94: 585-592, 2013. PMCID:PMC3832209

Lancaster CS, Sprowl JA, Walker AL, Hu S, Gibson AA, Sparreboom A. Modulation of OATP1B-type transporter function alters cellular uptake and disposition of platinum chemotherapeutics. Mol Cancer Ther 12: 1537-1544, 2013. PMCID:PMC3742713

Sprowl JA, Ciarimboli G, Lancaster CS, Giovinazzo H, Gibson AA, Du G, Janke L, Cavaletti G, Shields AF, Sparreboom A. Oxaliplatin-induced peripheral neurotoxicity is dependent on the organic cation transporter OCT2. Proc Natl Acad Sci USA 110: 11199-11204, 2013. PMCID:PMC3704038

Lancaster CS, Bruun GH, Peer CJ, Mikkelsen TS, Corydon TJ, Gibson AA, Hu S, Orwick SJ, Mathijssen RH, Figg WD, Baker SD, Sparreboom A. OATP1B1 polymorphism as a determinant of erythromycin disposition. Clin Pharmacol Ther 92: 642-650, 2012. PMCID:PMC3478421

De Graan A-J, Lancaster CS, Obaidat A, Hagenbuch B, Elens L, Friberg LE, De Bruijn P, Hu S, Gibson AA, Bruun GH, Corydon TJ, Mikkelsen TS, Walker AL, Du G, Loos WJ, Van Schaik RH, Baker SD, Mathijssen RH, Sparreboom A. Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin Cancer Res 18: 4433-4440, 2012. PMCID:PMC3464009

Sprowl JA, Gregorc V, Lazzari C, Filipski KK, Loos WJ, Sparreboom A. Association of ABCC2 polymorphisms with cisplatin disposition and efficacy. Clin Pharmacol Ther 91: 1022-1026, 2012. PMCID:PMC3482956

Hu C, Zuo Z, Lancaster CS, Hu S, Chen z, Rubnitz JE, Baker SD, Sparreboom A. Inhibition of OCTN2-mediated carnitine transport by etoposide. Mol Cancer Ther 11: 921-929, 2012. PMCID:PMC3466062

Ciarimboli G, Lancaster CS, Schlatter E, Franke RM, Sprowl JA, Pravenstädt H, Massmann V, Guckel D, Mathijssen RH, Yang W, Pui C-H, Relling MV, Herrmann E, Sparreboom A. Proximal tubular secretion of creatinine by organic cationic transporter OCT2 in cancer patients. Clin Cancer Res 18: 1101-1108, 2012. PMCID:PMC3288323

Ware RE, Despotovic JM, Mortier NA, Flanagan JM, He J, Smeltzer MP, Kimble AC,Aygun B, Wu S, Howard T, Sparreboom A. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood 118(18):4985-91, 2011.

Eechoute K, Franke RM, Loos WJ, Scherkenbach LA, Boere I, Verweij J, Gurney H, Kim RB, Tirona RG, Mathijssen RHJ Sparreboom A. Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther 89(6):816-20, 2011.

Franke RM, Carducci MA, Rudek MA, Baker SD, Sparreboom A. Castration-dependent pharmacokinetics of Docetaxel in patients with prostate cancer J Clin Oncol 28(30):4562-7, 2010.

Lancaster CS, Hu C, Franke RM, Filipski KK, Orwick SJ, Chen Z, Zuo Z, Loos WJ, Sparreboom A. Cisplatin-induced downregulation of OCTN2 affects carnitine wasting. Clin Cancer Res 16(19):4789-4799, 2010.

Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther 86(4):396-402, 2009.

Hu S, Chen Z, Franke, RM, Orwick S, Zhao M, Rudek MA, Sparreboom A, Baker SD. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res 15(19):6062-9, 2009.

Baker SD, Verweij J, Cusatis GA, Van Schaik RH, Marsh S, Orwick SJ, Franke RM, Hu S, Schuetz EG, Lamba V, Messersmith WA, Wolff AC, Carducci MA, Sparreboom A. Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther 85: 155-163, 2009.

Mathijssen RH, Sparreboom A. Influence of lean body weight on anticancer drug clearance. Clin Pharmacol Ther 85: 23-24, 2009.

Franke RM, Baker SD, Mathijssen RH, Schuetz EG, Sparreboom A. Influence of solute carriers on the pharmacokinetics of CYP3A4 probes. Clin Pharmacol Ther 84: 704-709, 2008.

Filipski KK, Loos WJ, Verweij J, Sparreboom A. Interaction of cisplatin with the human organic cation transporter OCT2. Clin Cancer Res 14: 3875-3880, 2008.

Hu S, Franke RM, Filipski KK, Hu C, Orwick SJ, De Bruijn EA, Burger H, Baker SD, Sparreboom A. Interaction of imatinib with organic ion carriers. Clin Cancer Res 14: 3141-3148, 2008.

Sparreboom A, Wolff AC, Mathijssen RH, Chatelut E, Rowinsky EK, Verweij J, Baker SD. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol 25: 4707-4713, 2007.

Van Erp NP, Gelderblom H, Karlsson MO, Li J, Zhao M, Ouwerkerk J, Nortier JW, Guchelaar H-J, Baker SD, Sparreboom A. Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. Clin Cancer Res 13: 7394-7400, 2007.

Gardner ER, Burger H, Van Schaik RH, Van Oosterom AT, De Bruijn EA, Guetens G, Prenen H, De Jong FA, Baker SD, Bates SE, Figg WD, Verweij J, Sparreboom A, Nooter K. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol Ther 80: 192-201, 2006.

Henningsson A, Marsh S, Loos WJ, Karlsson MO, Garsa A, Mross K, Mielke S, Vigano L, Locatelli A, Verweij J, Sparreboom A, McLeod HL. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res 11: 8097-8104, 2005.

Lepper ER, Baker SD, Permenter M, Ries N, Van Schaik RH, Schenk PW, Price DK, Ahn D, Smith NF, Cusatis G, Ingersoll RG, Bates SE, Mathijssen RH, Verweij J, Figg WD, Sparreboom A.  Impact of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.  Clin Cancer Res 11: 7398-7404, 2005.

Smith NF, Acharya MR, Desai N, Figg WD, Sparreboom A. Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 4: 815-818, 2005.

Baker SD, Li J, Ten Tije AJ, Figg WD, Graveland W, Verweij J, Sparreboom A. Relationship of exposure to unbound docetaxel and neutropenia. Clin Pharmacol Ther 77: 43-53, 2005.

Last update: March 2014